Takeda Pharmaceutical (NYSE:TAK - Get Free Report) is scheduled to be announcing its earnings results before the market opens on Thursday, May 9th.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, February 1st. The company reported $0.51 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 12.57% and a net margin of 6.90%. The business had revenue of $7.52 billion for the quarter. On average, analysts expect Takeda Pharmaceutical to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Takeda Pharmaceutical Trading Up 0.6 %
Shares of TAK traded up $0.08 during mid-day trading on Thursday, reaching $13.27. The stock had a trading volume of 1,033,508 shares, compared to its average volume of 1,790,775. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.06 and a quick ratio of 0.55. The business's fifty day moving average is $13.93 and its 200 day moving average is $14.14. Takeda Pharmaceutical has a 52-week low of $13.01 and a 52-week high of $17.11. The firm has a market cap of $42.00 billion, a price-to-earnings ratio of 20.11, a P/E/G ratio of 2.98 and a beta of 0.56.
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Further Reading
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
